Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)

Inclusion Criteria: * Patients, ages 18 years or older who have signed the informed consent * Has a qualifying skin and skin structure infection * Female patients must not be pregnant at the time of enrollment * Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug Exclusion Criteria: * Infections where the outcome is strongly influenced by factors other than protocol-defined treatment and procedures, that require antibacterial treatment for greater than 14 days * Evidence of significant immunological disease * Severe sepsis or septic shock * Has a history of hypersensitivity or allergic reaction to any tetracycline or to linezolid * Has received an investigational drug within past 30 days * Women who are pregnant or nursing